Fisher & Paykel Healthcare (ASX:FPH, NZE:FPH) said the 10% US tariffs on products manufactured in New Zealand will not significantly impact its fiscal 2025 net profit but are expected to drive higher costs in fiscal 2026, according to a Thursday filing with the Australian and New Zealand bourses.
About 55% of its production is based in New Zealand, with around 40% of its US volumes supplied from there, the filing added, the filing said.
Shares of the company fell almost 5% in New Zealand in recent Thursday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.